Premaitha Health

Premaitha Health is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome) and Trisomy 13 (Patau’s syndrome). The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA® test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctors’ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. Premaitha’s strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women.
Premaitha is listed on the London Stock Exchange’s Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK.

Manchester, GB
Size (employees)
43 (est)
Premaitha Health was founded in 2013 and is headquartered in Manchester, GB

Premaitha Health Office Locations

Premaitha Health has an office in Manchester
Manchester, GB (HQ)
Rutherford House 40 Pencroft Way

Premaitha Health Data and Metrics

Premaitha Health Financial Metrics

Premaitha Health's revenue was reported to be £2.5 m in FY, 2016 which is a 1754% increase from the previous period.

Revenue (FY, 2016)

2.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

701 k

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(12.1 m)

Market capitalization (18-Sep-2017)

18 m

Closing share price (18-Sep-2017)


Cash (31-Mar-2016)

5.3 m
Premaitha Health's current market capitalization is £18 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


257.7 k102.5 k132.3 k2.5 m

Revenue growth, %


Cost of goods sold

555.2 k1.8 m

Gross profit

(297.5 k)701 k
GBPFY, 2014FY, 2015FY, 2016


49.9 k2.7 m5.3 m

Accounts Receivable

60 k964.2 k

Current Assets

500.6 k4.3 m8.6 m


436.4 k1.3 m1.9 m
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(1.5 m)(5 m)(7 m)

Cash From Financing Activities

2 m7.5 m10.8 m

Income Taxes Paid

(39.5 k)39.5 k
GBPY, 2016


98.1 k

Financial Leverage

7.1 x
Show all financial metrics

Premaitha Health Market Value History

Traffic Overview of Premaitha Health

Premaitha Health Online and Social Media Presence

Premaitha Health News and Updates

Premaitha Health Company Life and Culture

You may also be interested in